Odyssey Health, Inc.

Odyssey Health, Inc. is a Nevada-based medical product development company focused on acquiring, licensing, and advancing healthcare technologies through its operating subsidiaries. Its reported pipeline includes the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device, with development and commercialization intended to occur through third-party partners and distributors.

0.01

0.01

— Odyssey Health, Inc.
%
CardioMap device40% Heart monitoring and screening technology under development for medical use.
Save-A-Life device40% Choking rescue device designed for emergency response and airway obstruction use.
Licensing and distribution rights15% Potential license fees, royalties, and distribution agreements for approved products.
Medical technology acquisition5% Acquisition of medical products, assets, and intellectual property for development.

Odyssey Health’s end customers are expected to be healthcare providers, distributors, and commercial partners that...

  • Healthcare providersprimary

    Hospitals, clinics, and care settings that would buy or use approved monitoring and rescue devices.

  • Medical device distributorsprimary

    Third-party distributors that sell the company’s products and provide market access.

  • Licensing partnersprimary

    Commercial partners that pay upfront fees and royalties to market or sublicense products.

  • Emergency-use end userssecondary

    Users and institutions that need choking rescue tools for rapid response situations.

Odyssey Health is headquartered in Las Vegas, Nevada, and is organized as a U.S. public company with subsidiaries in...

  • •Headquartered in Las Vegas, Nevada
  • •U.S. corporate base and primary regulatory home market
  • •Australia subsidiary supports international structure
  • •Planned commercialization in the United States and abroad
  • •International licensing is part of the growth model

The company’s strategy is to acquire or develop medical technologies, secure regulatory clearance, and then...

01
Obtain regulatory clearance for product candidatesshort-term

Commercial sales depend on FDA or other regulatory approval.

02
Build distribution and licensing partnershipsshort-term

Third-party channels are intended to accelerate market entry and revenue generation.

03
Broaden the technology platformmedium-term

Additional uses can increase the commercial value of the core technology base.

Odyssey Health faces the typical risks of an early-stage medical device developer, including regulatory approval risk,...

critical

Regulatory approval risk

Product candidates cannot be sold commercially until cleared or approved by regulators.

Scope
CardioMap and Save-A-Life
Materiality
high
high

Distribution network risk

The company expects third parties to market and sell products, which may not materialize or perform well.

Scope
U.S. and international channel partners
Materiality
high
high

Funding and going-concern risk

Development-stage operations require external capital before product revenue exists.

Scope
Corporate liquidity and development spending
Materiality
high
high

Intellectual property risk

The business depends on patents, trademarks, and proprietary technology to protect value.

Scope
Medical device technologies and acquired IP
Materiality
medium
Going concern assessment
Affects investor assessment of solvency and capital needs
Stock-based compensation
Affects operating loss and dilution analysis
Debt and interest expense
Affects net loss and cash flow interpretation
Intangible asset valuation and impairment
Could materially affect balance sheet and earnings

Ovid Therapeutics Inc.

OVID · Pharmaceutical Preparations

ODYSSEY MARINE EXPLORATION INC

OMEX · Water Transportation

Omada Health, Inc.

OMDA · Services-Health Services

Odysight.ai Inc.

ODYS · Services-Computer Integrated Systems Design

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

National Healthcare Properties, Inc.

NHP · Real Estate Investment Trusts

: 29.4.2026